Metagenomi Q2 Revenue Turns Negative on Ionis Catch-Up; Cash Burn Accelerates
MGX is trading near its 52-week low of $1.13 (6.2% above the low).
Summary
Metagenomi's Q2 revenue turned negative after a $2.6 million Ionis catch-up adjustment, while cash reserves fell to $120.7M from $160.8M at year-end. The accelerated cash burn and collaboration headwinds heighten financing risk for the micro-cap gene-editing company.
Key Events · Earnings and Guidance · MGX
-
Revenue Turns Negative
Q2 collaboration revenue was -$0.3M vs $8.5M a year ago, due to a $2.6M cumulative catch-up adjustment from modifying the Ionis agreement. The adjustment reflects reduced economics from the partnership.
-
Cash Burn Accelerates
Cash, equivalents, and marketable securities fell to $120.7M from $160.8M at year-end 2025. Operating cash burn was $40.7M in H1 2026, up from $44.1M in H1 2025, but revenue headwinds make the burn more concerning.
-
Ionis Agreement Modified
On April 1, 2026, the Ionis collaboration was modified: the exploratory research plan was discontinued, and a new performance obligation was added for one Wave 1 target. The change triggered the $2.6M revenue reversal.
-
Real Estate Impairment
A sublease of office space in April 2026 triggered a $0.6M non-cash impairment on the right-of-use asset, indicating downsizing and potential cost-cutting.
Analysis · MGX · Life Sciences
A sharp reversal in collaboration revenue marked Metagenomi's second quarter, swinging to a negative $0.3 million from $8.5 million a year ago. The culprit was a $2.6 million cumulative catch-up adjustment triggered by changes to the Ionis partnership, which now carries reduced economics for a once-critical revenue stream. Meanwhile, cash, equivalents, and marketable securities dwindled to $120.7 million from $160.8 million at year-end, reflecting a $40.7 million operating cash burn in the first half. Although management asserts that cash is sufficient for at least 12 months, the accelerated burn rate and revenue headwinds raise near-term financing risk for this $46 million market cap biotech. A $0.6 million impairment on a sublease further signals real estate downsizing, while an ongoing securities class action adds legal overhang.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.4% of the 1059 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MGX was trading at $1.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $46.3M. The 52-week trading range was $1.13 to $3.95. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.